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Objective: This study was carried out to compare the clinical outcome of elective single cleavage-embryo transfer (eSCET) to that of elective 
single blastocyst-embryo transfer (eSBET) in human IVF-ET.
Methods: This study was a retrospective study which analyzed for 614 women who visited the Daegu Maria Clinic from August 2008 to De-
cember 2009. All were under 37 years old and had more than 8 mm of endometrial thickness on the day of hCG administration and at least one 
good quality embryo on day 3. The eSCETs were performed on day 3 (n=450) and the eSBETs were conducted on day 5 (n=164).
Results: The numbers of retrieved oocytes, fertilized oocytes, and day 3 good quality embryos were significantly lower in the eSCET group (12.1 
±6.0, 8.2±4.6, and 4.2±3.1, respectively) compared to the eSBET group (16.7±7.2, 12.1±5.0, and 8.5±4.5, respectively; p<0.001). However, 
the clinical pregnancy, implantation, on-going pregnancy, and live birth rates of the eSCET group (46.7, 46.9, 40.0, and 36.7%, respectively) were 
not statistically different from those of the eSBET group (51.2, 51.8, 45.1, and 43.9%, respectively; p=0.318, 0.278, 0.254, and 0.103, respective-
ly).
Conclusion: These results suggested that elective single embryo transfer should be performed regardless of the developmental stage to wom-
en less than 37 years old who had more than 8 mm of endometrial thickness on the hCG administration day and at least one good quality em-
bryo on day 3 in order to reduce the twin pregnancy rate without reducing the whole pregnancy rate.
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Introduction
Multiple embryos have been transferred into the uterine cavity in 
order to maintain an acceptable pregnancy rate in IVF-ET programs. 
However, this had a high risk of complications including premature 
birth, low birth weight infants, intrauterine growth retardation, peri-
natal death, and cerebral palsy. It has been concluded that minimiz-
ing the number of transferred embryos is the best way to prevent 
those side effects. A 22% multiple birth rate was reported in the Eu-
rope in 2004 [1] and a 31% rate in the US in 2006 [2]. However, the 
multiple birth rate of Korea in 2006 was reported to be high as 33.8% 
[3]. To reduce multiple pregnancies, in 2008 the Korean Ministry of 
Health and Welfare recommended transferring one embryo on day 4 
or 5 or two embryos on day 2 or 3 for patients who are less than 35 
years of age with a good prognosis. A voluntary reduction in the num-
ber of transferred embryos to two from three resulted in an almost 
complete elimination of triplet pregnancies, while the pregnancy rate 
remained at approximately 35%--similar to that for three embryos, 
and the twin birth rate became 25% [4]. In addition, Kang et al. [5] 
reported that 60.7% of clinical pregnancies and 32.3% of multiple 
pregnancies were achieved for women less than 36 years old on day 
3, resulting from two cleavage embryo transfer. In light of the above 
research, transferring just two embryos for patients with a good pro-
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gnosis could not dramatically decrease multiple pregnancies. 
One of the best ways to maintain a reasonable pregnancy rate while 
still reducing the number of multiple births in human IVF-ET would 
be to select and transfer a single embryo with the best quality of many 
embryos generated from a cohort. Actually, it was reported that the 
Nordic countries have successfully implemented a policy of single 
embryo transfer. In Sweden, for example, single embryo transfer was 
conducted for 70% of all patients [6]. An acceptable pregnancy rate 
must be maintained in order to perform single embryo transfer. Al-
though most clinics have not performed single embryo transfer due 
to fears that the pregnancy rate could be lowered by reducing the 
number of transferred embryos, previous studies including more than 
100 cycles showed that the clinical pregnancy and delivery rates of 
elective single cleavage–embryo transfer (eSCET) were similar to those 
of elective double cleavage–embryo transfer (eDCET) [5,7,8]. Like-
wise, it has been reported that the clinical pregnancy rate of elective 
single blastocyst–embryo transfer (eSBET) was similar to that of elec-
tive double blastocyst–embryo transfer (eDBET) on day 5 [9]. 
It would be difficult to accurately select the most competent of day 
3 embryos for eSCET [10,11]. Bavister [12] reported that morula- or 
blastocyst-stage embryo transfer resulted in a significantly higher 
implantation rate than cleavage-stage embryo transfer in many mam-
malian species. Similarly, Gardner et al. [13] suggested that transfer-
ring blastocyst-stage embryos will enhance the likelihood of preg-
nancy. Also, some studies have shown that day 5 eSBET resulted in a 
significantly higher pregnancy rate [14-16] and delivery rate [15,16] 
compared with day 2 or 3 eSCET in selected groups. These results sug-
gest that eSBET is one method that could reduce the multiple preg-
nancy rate while maintaining an acceptable pregnancy rate. Howev-
er, Guerif et al. [14] showed that there was no statistically significant 
difference in the cumulative pregnancy and birth rates of eSCET and 
eSBET groups, including fresh and frozen embryo transfers. Transfer-
ring of blastocyst-stage embryos into the uterine cavity would be 
identical to the time of natural pregnancy [17]. The risk of aneuploidy 
in a blastocyst-stage embryo would be also lower than a cleavage-
stage embryo [18,19]. However, there was no clear evidence that the 
blastocyst-stage embryo transfer resulted in a higher clinical outcome 
than the cleavage-stage embryo transfer [20]. Moreover, it has been 
reported that the implantation rate of the cleavage-stage embryo 
transfer was similar to that of the blastocyst-stage embryo transfer 
for patients with good prognosis [21]. It would show a higher cancel-
lation rate due to failed embryo development to the blastocyst stage 
[22]. Also, it has been reported that transfer of blastocyst-stage em-
bryo is related to a higher incidence of monozygotic twins [23], an al-
tered sex ratio of births [24], and the possibilities of epigenetic modi-
fication [25]. Consequently, the optimal time for embryo transfer still 
remains controversial. 
This study was carried out to compare the clinical outcome of eSCET 
to that of eSBET for patients with a good prognosis based on age, en-
dometrial thickness, and quality of embryo in human IVF-ET.
Methods 
1. Patient population 
This study was performed for 614 women who visited the Daegu 
Maria Clinic from August 2008 to December 2009. They were all un-
der 37 years old and had more than 8 mm of endometrial thickness 
on the day of hCG administration, more than 2 fertilized embryos, 
and at least one good quality embryo on day 3. This study did not in-
clude oocyte donation cycles. 
2. Ovarian stimulation and oocyte retrieval
Ovarian stimulation was undertaken by using the GnRH agonist 
long protocol or GnRH antagonist protocol and recombinant FSH 
(Gonal-F; Merck Serono, Darmstadt, Germany). 10,000 IU of hCG (IVF-
C; LG Life Science, Daejon, Korea) was injected when more than two 
follicles 17-18 mm in diameter were visible on ultrasonography. Oo-
cyte retrieval was undertaken by transvaginal ultrasound-guided as-
piration after 36 hours of hCG administration. The maturity of collect-
ed oocytes was determined depending on the features of corona ra-
diata. The oocytes were washed in MRC#OW medium (Biosupply Co., 
Seoul, Korea) according to their maturity--mature, intermediate and 
immature, and then cultured in MRC#D01 medium (Biosupply Co.) 
until insemination or intracytoplasmic sperm injection (ICSI). 
3. Fertilization induction
In vitro fertilization was induced by using conventional insemina-
tion or ICSI. Insemination was conducted in MRC#D01 medium (Bio-
supply Co.). After doing ICSI, oocyte culture was also performed in 
MRC#D01 medium (Biosupply Co.). Within the 16 to 18 hours, the 
oocyte with two pronuclei and a second polar body was regarded to 
be normally fertilized. The normally fertilized embryos were cultured 
until eSCET or eSBET was performed. 
4. Embryo culture
All the zygotes were co-cultured with autologous cumulus cells 
(ACC) in 20 µL of MRC#D16 medium (YS medium [26]; Biosupply Co.) 
containing autologous follicular fluid (AFF). Culture medium was ex-
changed for pre-equilibrated fresh medium every morning. AFF was 
collected from follicles that produced healthy mature oocytes with a 
clear corona radiata. AFF was used for culture after inactivation at 56°C 
for 30 minutes and sterilization with a 0.22 µm filter in turns followed 
by centrifuging for 15 minutes at 3,000 rpm. ACCs were also prepared 
in a 5 µL micro droplet of an organ culture dish (353653, BD Falcon; www.eCERM.org
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Becton Dickinson Labware, Franklin Lakes, NJ, USA) under MRC#Oil 
(Biosupply Co.) by seeding its single cells followed by excising from a 
clear corona radiata of healthy cumuli and digesting with MRC#Hyase 
(Biosupply Co.). The first 48 hours of co-culture was supplemented 
with 10% AFF, and during the next 48 hours 20% AFF was added. In 
the middle of co-culture, only one embryo in the eSCET group was 
transferred on day 3 and the rest of the embryos were co-cultured 
until day 5 or 6. Similarly, only one embryo in the eSBET group was 
transferred on day 5. The surplus embryos that reached the blasto-
cyst stage on day 5 or 6 were thereafter cryo-preserved by vitrifying 
one or two units per ampoule based on their quality. 
5. Luteal phase support and embryo transfer
The luteal phase was supported by administration of Crinone gel 
(90 mg, Merck Serono) and Utrogestan (100 mg, Lab. Besins Int., Par-
is, France) for 14 days after oocyte retrieval. The Crinon gel was taken 
once a day vaginally, while the Utrogestan was taken orally three times 
a day. 
The quality of cleavage-stage embryos was assessed in the morn-
ing of day 3. A “good” quality day 3 embryo was defined as having 
more than 7-blastomeres of equal size and less than 20% fragmenta-
tion. The quality of blastocyst-stage embryos was assessed in the 
morning of day 5, which was categorized according to the criteria of 
Gardner and Schoolcraft [27]. The scoring system was based on the 
degree of expansion and hatching status of the blastocoel cavity (1-
6), the size of the inner cell mass (A-C), and the development of the 
trophectoderm (A-C). It was standard that the blastocyst embryo 
transfer would be performed for women with more than 4 good em-
bryos on day 3. However, most of the women with embryos produced 
by ICSI were excluded from this standard although they had several 
good quality embryos due to a fear of ET failure. The eSCET or eSBET 
was completed by transferring a single best embryo into the uterine 
cavity in each group. 
6. Embryo cryopreservation 
After eSCET or eSBET, the surplus embryos were cocultured to day 5 
or 6 with the ACC in the MRC#D16 containing 20% AFF. Only the nor-
mal embryos that reached the blastocyst stage were selected for cryo-
preservation based on the healthiness of trophectoderm cells and 
the size of the inner cell mass. The embryos were artificially shrunken 
for dehydration of the blastocoel using two 29-gauge needles, and 
then incubated for 5 minutes in MRC#CBS (Biosupply Co.). Vitrifica-
tion of the embryos was carried out after exposure to equilibration 
solution for 1.5 minutes. The equilibration solution was MRC#CBS 
containing 20% (v/v) ethylene glycol (EG), while the vitrification solu-
tion was MRC#CBS supplemented with 40% (v/v) EG, 18% (w/v) fi-
coll, and 0.3 M sucrose. The equilibrated embryos were transferred 
into vitrification solution, loaded onto an EM grid, and directly plunged 
in liquid nitrogen within 30 seconds. Finally, the EM grid was moved 
in a cryovial previously submerged under liquid nitrogen. The cryovi-
al was stored in liquid nitrogen. 
7. Pregnancy and implantation 
Serum β-hCG concentration was measured 14 days after oocyte re-
trieval to verify pregnancy. Follow-up inspection was continuously 
conducted for women whose serum β-hCG concentration was posi-
tive. Clinical pregnancy was judged by observation of the gestational 
sac on vaginal ultrasonography after 6-7 weeks of gestation. A preg-
nancy with fetal heartbeat for longer than 10 weeks was also defined 
as an ongoing pregnancy. The implantation rate was indicated as the 
proportion of the gestational sacs to the transferred embryos. 
8. Statistical analysis 
Statistical analysis was performed with SPSS ver. 14.0 (SPSS Inc., 
Chicago, IL, USA) program, and the average value was expressed as 
the mean±standard deviation. For comparison of the continuous 
variables, the Student’s t-test was used and for comparison of non 
continuous variable, the chi-square test was used. Results were con-
sidered statistically significant if p<0.05. 
Results 
Of the women under 37 years old who visited the Daegu Maria 
Clinic for IVF-ET treatment from August 2008 to December 2009, 614 
cases had an endometrial thickness was more than 8 mm on the day 
of hCG administration, more than 2 fertilized embryos, and at least 
one good quality embryo on day 3. eSBET was performed for 164 
women on day 5, and eSCET was conducted for 450 women on day 
3. The characteristics of the eSCET group compared to the eSBET 
group were shown in Table 1. There was no difference between the 
eSBET and eSCET groups in terms of the age of patients, number of 
previous IVF cycles, endometrial thickness at hCG administration, or 
duration of infertility. However, the tubal factor rate of the eSCET 
group was significantly lower than that of the eSBET group in etiolo-
gy of infertility (16.4% vs. 26.8%; p<0.004), while the male factor 
rate of the eSCET group was significantly higher than that of the eS-
BET group (30.4% vs. 17.1%; p<0.001) (Table 1). On the other hand, 
there was no difference in the ovulation induction of the eSBET and 
eSCET groups. The GnRH agonist long protocol was applied to most 
of the women in each group as shown in Table 1 (eSBET, 96.3%; eS-
CET, 97.6%). Accordingly, the GnRH antagonist short protocol was 
used for a few women in each group (eSBET, 3.7%; eSCET, 2.4%). 
The proportion of ICSI attempts was significantly higher in the eS-
CET group compared with the eSBET group (48.0% vs. 20.7%; p<   doi: 10.5653/cerm.2011.38.1.53
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0.001), while that of conventional IVF was significantly lower in the 
eSCET group than in the eSBET group (52.0% vs. 79.3%; p<0.001) as 
shown in Table 2. Incidentally, there was no difference between the 
conventional IVF and ICSI rates in the eSCET group (52.0% vs. 48.0%), 
but those of the eSBET group were significantly different (79.3% vs. 
20.7%; p<0.001). On the other hand, the numbers of retrieved and 
matured oocytes were significantly fewer in the eSCET group (12.1± 
6.0 and 9.6±5.4, respectively) compared to the eSBET group (16.7± 
7.2 and 13.4±6.1, respectively; p<0.001), but those within each 
group were the same as shown in Table 2. Similarly, the numbers of 
fertilized oocytes, good quality embryos, and cryopreserved blasto-
cysts were significantly fewer in the eSCET group (8.2±4.6, 4.2±3.1, 
and 3.1±2.6, respectively) than those of the eSBET group (12.1±5.0, 
8.5±4.5, and 6.5±3.7, respectively; p<0.001), but there was no dif-
ference between conventional IVF and ICSI cycles in those of each 
group (Table 2). Moreover, the fertilization, developmental compe-
tency, and cryopreservation rates had a tendency to become lower 
in the eSCET group (85.4%, 51.2%, and 43.1%, respectively) com-
pared to the eSBET group (90.3%, 69.6%, and 58.6%, respectively), 
but there was no difference between conventional IVF and ICSI cy-
cles in those of each group (data not shown).
The clinical outcomes of the eSBET and eSCET groups are shown in 
Table 3. The clinical and ongoing pregnancy rates of the eSCET group 
(46.7% and 40.0%, respectively) showed a tendency to become low-
er than those of the eSBET group (51.2% and 45.1%, respectively), 
but there was no statistical significance between the two groups in 
those rates (p=0.318 and 0.254, respectively). The implantation rates 
of the eSBET and eSCET groups also did not show an appreciable dif-
ference (51.8% vs. 46.9%; p=0.278). The ectopic pregnancy rates were 
similar in the eSBET and eSCET groups, at 1.2% and 1.3%, respective-
ly. Only one case of a pregnancy with monozygotic twins was found 
in each group (eSBET, 1.2% vs. eSCET, 0.5%; p=0.501). The abortion 





Age (yr) 31.7±2.9 32.0±2.8 NS
No. of previous IVF cycle 0.5±1.1 0.4±0.8 NS
Endometrial thickness at hCG 
   triggering (mm)
10.6±1.5 10.8±1.5 NS
Duration of infertility (mo)  47.9±27.6 48.9±27.1 NS
Etiology of infertility
Tubal 44 (26.8) 74 (16.4) <0.004
Endometriosis 3 (1.8) 22 (4.9) NS
Anovulation 12 (7.3) 18 (4.0) NS
Male factor 28 (17.1) 137 (30.4) <0.001
Mixed 42 (25.6) 98 (21.8) NS
Other, including unknown 35 (21.3) 101 (22.4) NS
Ovulation induction
GnRH agonist long 158 (96.3) 439 (97.6) NS
GnRH antagonist short   6 (3.7)  11 (2.4) NS
Values are presented as mean±SD or number (%).
eSBET, elective single blastocyst-embryo transfer; eSCET, elective single clea-
vage-embryo transfer; IVF, in vitro fertilization;  hCG, human chorionic gona-
dotropin; GnRH, gonadotropin-releasing hormone; NS, not significant.




IVF ICSI Total IVF ICSI Total
No. of cycles 130 (79.3) 34 (20.7) 164 (26.7) 234 (52.0) 216 (48.0) 450 (73.3) <0.001
No. of retrieved oocytes 16.3±6.7 18.6±8.6 16.7±7.2 12.0±5.7 12.1±6.4 12.1±6.0 <0.001
No. of matured oocytes 12.7±5.4 16.4±7.6 13.4±6.1   9.2±4.9 10.0±5.8   9.6±5.4 <0.001
No. of fertilized oocytes 11.7±4.8 13.5±5.7 12.1±5.0   7.9±4.2   8.5±4.9   8.2±4.6 <0.001
No. of good quality embryos on day 3   8.3±4.1   9.4±5.7   8.5±4.5   3.9±2.7   4.7±3.5   4.2±3.1 <0.001
No. of cryopreserved blastocysts   6.4±3.4   7.1±4.7   6.5±3.7   2.8±2.4   3.3±2.9   3.1±2.6 <0.001
Values are presented as number (%) or mean±SD.
p-value between eSBET and eSCET regardless of fertilization protocol.
eSBET, elective single blastocyst-embryo transfer; eSCET, elective single cleavage-embryo transfer; IVF, in vitro fertilization; ICSI, intracytoplasmic sperm injection. 





Clinical pregnancies 84 (51.2) 210 (46.7) 0.318
Extrauterine pregnancies 2 (1.2) 6 (1.3) 0.912
Gestational sacs 85 (51.8) 211 (46.9) 0.278
Twin pregnancies 1 (1.2) 1 (0.5) 0.501
On-going pregnancies 74 (45.1) 180 (40.0) 0.254
Miscarriage >10 wk 1 (1.4) 12 (6.7) 0.080
Lost to follow-up 1 (1.4) 3 (1.7) 0.855
Live birth 72 (43.9) 165 (36.7) 0.103
   Singleton 71 (98.6) 164 (99.4) 0.545
   Twin 1 (1.4) 1 (0.6) 0.545
   Preterm birth <37 wk 6 (8.3) 9 (5.5) 0.403
   Low birth weight infants <2,500 g 3 (4.1) 11 (6.6) 0.445
The continuous variables are expressed as number (rate).
eSBET, elective single blastocyst-embryo transfer; eSCET, elective single clea-
vage-embryo transfer. www.eCERM.org
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rate following 10-weeks showed a tendency to be higher in the eS-
CET group compared to the eSBET group, with no statistical differ-
ence (6.7% vs. 1.4%; p=0.080). The live birth rate of the eSCET group 
was statistically similar to that of the eSBET group (36.7% vs. 43.9%; 
p=0.103). Moreover, the preterm (before 37 weeks) and low weight 
(less than 2,500 g) birth rates of the eSCET group (5.5% and 6.6%, re-
spectively) were statistically identical to those of the eSBET group 
(8.3% and 4.1%). Finally, most of the live birth babies were singletons 
(eSBET, 98.6% vs. eSCET, 99.4%), which was similar for the two groups. 
Discussion 
The present study showed that the clinical pregnancy, implantation, 
on-going pregnancy, and live birth rates of the eSCET group were 
not statistically different from those of the eSBET group although the 
numbers of retrieved oocytes, fertilized oocytes, and day 3 good qual-
ity embryos were significantly lower in the eSCET group than in the 
eSBET group (Table 3). Only one case of a multiple pregnancy with 
monozygotic twins was found in each group, while the live birth rates 
tended to be lower in the eSCET group than the eSBET group but 
there was no statistical significance between the two groups. The 
preterm and low weight birth rates also showed a tendency to be 
lower in the eSCET group than the eSBET group, with no statistical 
difference between the two groups (Table 3). However, Papanikolaou 
et al. [15], Zech et al. [16], and Guerif et al. [14] had reported that the 
pregnancy and birth rates were lower in those undergoing eSCET 
than in those undergoing eSBET. Taken together, it was suggested 
that the clinical outcome of the eSCET group should be similar to 
that of the eSBET group if women in whom a single embryo will be 
replaced are selected on the basis of several factors, including age, 
endometrial thickness, embryo number, and day 3 embryo qualities. 
A weakness of the present study was that it was a retrospective 
study. Thus, the proportion of tubal factor among the etiology of in-
fertility was significantly lower in the eSCET group than the eSBET 
group (p<0.004), whereas the proportion of male factor was signifi-
cantly higher in the eSCET group than the eSBET group (p<0.001) 
(Table 1). Also, the eSBET was actually assigned to the women with 
full procurement of good quality embryos on the 3rd day to prevent 
the cancellation of blastula transfer among the embryos fertilized by 
conventional insemination. Thus, it was concluded that the number 
of retrieved oocytes, normal zygotes and day 3 good quality embry-
os were much higher in the eSBET group than the eSCET group (Ta-
ble 2). Meanwhile, the attempt ratio of ICSI was significantly higher 
in the eSCET group than the eSBET group (p<0.001), resulting from 
the report of Miller and Smith [28] that the blastula formation rate 
was lower in the oocytes fertilized by ICSI than those fertilized by con-
ventional insemination. It was also concluded that more ICSI cycles 
were composed in the eSCET group as the embryos derived from ICSI 
were transferred as close to day 3 as possible though there were a 
large number of good quality embryos. In the present study, the blas-
tula rates of embryos derived from ICSI could not be demonstrated 
because they were not assessed. It was found that the clinical preg-
nancy rate derived from ICSI was similar to that of conventional in-
semination in the eSBET group (50% vs. 51.5%). On the other hand, it 
was also observed that the clinical pregnancy rates between ICSI and 
conventional insemination of the eSCET group were similar (46.3% 
vs. 47.0%). Likewise, the birth rates derived from ICSI between the 
eSBET and eSCET groups were 44.1% (15/34) and 36.6% (79/216), re-
spectively, which were not different from 43.9% (57/130) and 36.8% 
(86/234), respectively, of conventional insemination in each group. 
Accordingly, it was concluded that although there was a significant 
difference between the two groups in the ICSI usage ratio, fertiliza-
tion methods were careless about the clinical pregnancy and birth 
rates in both groups. 
Previous studies have found that a higher implantation rate could 
be achieved by transferring blastulas than by transferring cleavage-
stage embryos for several reasons. Magli et al. [18] reported that ap-
proximately 51% of “top quality” day 3 embryos had aneuploidy, 
which was higher than 35% of blastocysts. They mentioned that the 
embryos with genetic abnormalities have difficulty developing to 
the blastocyst stage, so that transfer of blastulas will guide to select-
ing better quality embryos compared to cleavage-stage embryos 
[18,19]. Also, Gardner et al. [17] reported that transferring the cleav-
age- stage embryos to the uterine cavity can damage the develop-
mental competence of embryos, resulting from the stress of metabo-
lism as the oviduct and uterus provide different nutritional environ-
ments to embryos. Based on the given reasons, previous studies on 
the eSCET and eSBET have reported that the clinical pregnancy and 
birth rates of those undergoing eSBET were significantly higher than 
those undergoing eSCET [14-16]. However, the present study showed 
that the clinical pregnancy and birth rates of the eSBET group had a 
tendency to be higher with eSCET but there was no statistical differ-
ence between the two groups (Table 3). It was concluded that the re-
sults were attributed to selection of women less than 37 years old 
who possessed more than 8 mm of endometrial thickness on hCG 
administration day, more than two fertilized embryos, and at least 
one good quality embryo on day 3.
 When one embryo is transferred in IVF-ET programs, monozygotic 
pregnancies rarely occurred, while dizygotic twin pregnancies were 
completely prevented. The frequency of monozygotic twin pregnan-
cies has been reported to be approximately 2-5% following eSBET. In 
addition, Papanikolaou et al. [15] reported that monozygotic twin 
pregnancies were 2% in the eSCET group, while there were no cases 
of monozygotic twins in the eSBET group. In the present study, the   doi: 10.5653/cerm.2011.38.1.53
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proportion of monozygotic twin pregnancies was similar between 
the eSBET and eSCET groups (0.6% vs. 0.5%). These were identical to 
the result of natural pregnancy, which was 1/330 [29]. On the other 
hand, monozygotic pregnancies were reported to be increased by 
transferring blastulas rather than cleavage-stage embryos [23], re-
sulting in higher perinatal morbidity and mortality compared to di-
zygotic twins [30]. Guerif et al. [14] reported that the monozygotic 
twin birth rate was slightly higher in the eSBET group than the eSCET 
group (3.8% vs. 1.6%) but there was no statistical significance among 
any of the groups [14]. da Costa et al. [31] reported that the monozy-
gotic twin pregnancies were increased by transfer of the blastula, and 
the reason might be due to more damage and hardening of the zona 
pellucida from in vitro culture environment compared to cleavage-
stage embryos. Therefore, it is considered to be necessary for further 
research about the correlation between blastula transfer and mono-
zygotic twins. 
Ectopic pregnancies have been reported to occur in approximately 
2-5% of clinical pregnancies after IVF-ET [32,33]. Stimulations caused 
by collecting the ovum, plus culture medium injected for transferring 
embryos and methods of transferring can be major factors of ectopic 
pregnancies. It is considered that uterine contraction make transferred 
embryos move toward the fallopian tube, caused by those factors. 
Fanchin et al. [34] indicated that ectopic pregnancies should be de-
creased by transfer of blastulas compared to cleavage-stage embryos 
as uterine contractility will gradually decline according to the time 
following oocyte retrieval. Schoolcraft et al. [35] also indicated that 
the diameter of the blastula is larger than that of the cleavage-stage 
embryo, so that blastula transfer should reduce the movement of the 
embryo to the fallopian tube. In the present study, the ectopic preg-
nancies of eSCET group were 2.8% (6/216), which was identical to 
2.3% (2/86) of the eSBET group. On the other hand, there was a case 
in which blastula transfer increased ectopic pregnancy compared to 
cleavage-stage embryo transfer [36]. 
In 2009, the National Statistical Office announced that the preterm 
birth and low weight birth rates of singleton pregnancies were 2.2% 
and 3.5%, respectively, whereas those of multiple pregnancies were 
28.9% and 54.4%, respectively. In the present study, the preterm birth 
and low weight birth rates derived from single embryo transfer were 
6.0% and 5.9%, respectively, which was to exclude 2 cases of mono-
zygotic twin pregnancies (there were 50% of preterm and low weight 
birth among these). These results indicated that the premature birth 
and low weight birth infant should clearly be increased by multiple 
pregnancies. Thus, Daegu Maria Clinic has gradually reduced the num-
ber of transferred embryos to minimize multiple pregnancies in since 
2007. In 2010, only an elective single embryo was transferred to about 
55% of women. In fact, most of the women refused this method for 
fear that the pregnancy rate could be reduced. However, once the re-
sistance had been almost eliminated as they understood the fact that 
the overall pregnancy rate had no difference: although only single 
embryo is transferred, the surplus embryos are stored, and if more 
than 2 embryos are transferred to women, complications can occur 
to women as a result of multiple pregnancies. Currently, the average 
number of embryos transferred at Daegu Maria Clinic was about 1.4 
units, and vitrification of the surplus embryos was undertaken for 
about 68% of women. 
In conclusion, these results suggest that elective single embryo 
should be transferred regardless of the developmental stage to wom-
en less than 37 years old who had more than 8 mm of endometrial 
thickness on hCG administration day and at least one good quality 
embryo on day 3 to reduce the twin pregnancy rate, without reduc-
ing the whole pregnancy rate. It is concluded that elective single em-
bryo transfer will dramatically improve the cumulative pregnancy 
rate because enough surplus embryos can be preserved for many 
patients. 
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